Loading...
Loading...
INO| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | 30.2M |
| Gross Profit | -30.1M |
| Operating Expense | 44.1M |
| Operating I/L | -44.0M |
| Other Income/Expense | 3.3M |
| Interest Income | 2.2M |
| Pretax | -40.6M |
| Income Tax Expense | -2,989.4M |
| Net Income/Loss | 2,948.7M |
Inovio Pharmaceuticals, Inc. is a biotechnology company specializing in the development and commercialization of DNA medicines for the treatment and prevention of diseases such as human papillomavirus (HPV), cancer, and infectious diseases. The company's DNA medicines platform utilizes SynCon for precise DNA sequence optimization and CELLECTRA smart devices for efficient DNA plasmid delivery. Inovio conducts clinical studies for various HPV-associated precancers and cancers, as well as other disorders including glioblastoma multiforme, HIV, Ebola, and more. The company generates revenue through partnerships, collaborations, and agreements with organizations and institutions for the development and support of its investigational DNA vaccines and medicines.
